Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study

Agata Bielecka-Dabrowa, Jan Henryk Goch, Jacek Rysz, Marek Maciejewski, Ravi Desai, Wilbert S Aronow, Maciej Banach, Agata Bielecka-Dabrowa, Jan Henryk Goch, Jacek Rysz, Marek Maciejewski, Ravi Desai, Wilbert S Aronow, Maciej Banach

Abstract

Introduction: The aim of the study was to assess the influence of co-existing atrial fibrillation (AF) on inflammatory condition factors, left ventricular function, clinical course and the efficacy of statin treatment of congestive heart failure in the course of dilated cardiomyopathy (DCM).

Material and methods: In a prospective, randomized, open-label study, 69 patients with DCM and left ventricular ejection fraction (LVEF) < or =40% were divided into two groups, with and without AF, who were treated according to the recommended standards. 68% of patients from the group with AF and 59% of patients from the group without AF were administered atorvastatin 40 mg daily for 8 weeks and 10 mg for next 4 months. Clinical examination with the assessment of body mass index (BMI) and waist size were followed by routine laboratory tests, measurement of concentration of tumor necrosis factor (TNF-alpha), interleukin-6 (IL-6), and IL-10 in blood plasma, N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in blood serum, echocardiographic examination, and the assessment of exercise capacity in 6-minute walk test (6-MWT). After six months, morbidity rate and the number of heart failure hospitalizations were also observed.

Results: In the whole population of patients, a significantly higher concentration of NT-proBNP was observed in the AF group (2669 +/- 2192 vs 1540 +/- 1067, p = 0.02). After statin treatment, in patients with DCM and co-existing AF, higher values of NT-proBNP and IL-6 were observed compared to non-AF patients (1530 +/- 1054 vs 1006 +/- 1195, p = 0.04 and (14.16 +/- 13.40 vs 6.74 +/- 5.45, p = 0.02, respectively).

Conclusion: In patients with DCM and co-existing AF, a weaker effect of atorvastatin concerning the reduction of IL-6 and NT-proBNP concentration was observed than in patients without atrial fibrillation.

Trial registration: ClinicalTrials.gov NCT01015144.

Figures

Figure 1
Figure 1
The comparison of IL-6 level in AF and non-AF patients treated with atorvastatin.

References

    1. Viswanathan MN, Page RL. Pharmacological therapy for atrial fibrillation: current options and new agents. Expert Opin Investig Drugs. 2009;18(4):417–431. doi: 10.1517/13543780902773410.
    1. Aronow WS, Banach M. Atrial Fibrillation: The New Epidemic of the Ageing World. J Atrial Fibrillation. 2009;1:337–361.
    1. Grönefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther. 2003;8(2):107–113. doi: 10.1177/107424840300800203.
    1. Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker W, Galanti A, Rysz J, Camm JA, White CM, Alfieri O. Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol. 2010. in press .
    1. Kaski JP, Elliott P. ESC Working Group. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz. 2007;32(6):446–51. doi: 10.1007/s00059-007-3045-5.
    1. Kellwellis-Opara A, Dörner A, Poller WC, Noutsias M, Kühl U, Schultheiss HP, Pauschinger M. Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol. 2007;96:469–480. doi: 10.1007/s00392-007-0524-x.
    1. Seiler J, Stevenson WG. Atrial fibrillation in congestive heart failure. Cardiol Rev. 2010;18(1):38–50. doi: 10.1097/CRD.0b013e3181c21cff.
    1. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009;15(12):MS12–23.
    1. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit. 2009;15(12):MS1–5.
    1. Wassmann S, Laufs U, Baumer AT, Müller K, Konkol Ch, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646–654.
    1. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res. 2006;98:730–742. doi: 10.1161/01.RES.0000216039.75913.9e.
    1. Wainwright G, Mascitelli L, Goldstein MR. Cholesterol-lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes? Arch Med Sci. 2009;5(3):289–295.
    1. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285–288.
    1. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sánchez-Pascuala R, Hernández G, Díaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719. doi: 10.1172/JCI1500.
    1. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmański R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol. 2006;48(4):143–7. doi: 10.1097/01.fjc.0000246150.52382.07.
    1. Laufs U, La Fata V, Plutzky J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135.
    1. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, Trikas A, Pitsavos C, Stefanadis C. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart. 2005;91:27–31. doi: 10.1136/hrt.2003.027110.
    1. Engvall E, Perlman P. Enzyme-linked immunosorbent assay (ELISA). Quantative assay of immunoglobulin G. Immunochemistry. 1971;9:871–874. doi: 10.1016/0019-2791(71)90454-X.
    1. Brembilla-Perrot B, Marçon O, Chometon F, Groben L, Claudon O, Terrier de la Chaise A, Louis P, Blangy H, Sadoul N, Selton O, Ammar S, Abbas M, Juillière Y. Significance of permanent atrial fibrillation in idiopathic dilated cardiomyopathy. Ann Cardiol Angeiol (Paris) 2007;56(3):107–110. doi: 10.1016/j.ancard.2007.02.003.
    1. Parthenakis FI, Patrianakos AP, Skalidis EI, Diakakis GF, Zacharis EA, Chlouverakis G, Karalis IK, Vardas PE. Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol. 2007;118(2):206–214. doi: 10.1016/j.ijcard.2006.03.090.
    1. Wojtkowska I, Sobkowicz B, Musiał WJ, Kozuch M. Persistent atrial fibrillation as a prognostic factor of outcome in patients with advanced heart failure. Kardiol Pol. 2006;64(8):777–783.
    1. Calò L, De Ruvo E, Sette A, Sciarra L, Scioli R, Sebastiani F, Topai M, Iulianella R, Navone G, Lioy E, Gaita F. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown) 2007;8(3):138–143.
    1. Piechota M, Banach M, Jacoń A, Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett. 2008;13(2):155–81. doi: 10.2478/s11658-007-0046-6.
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1.
    1. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, Shalaby A, Levine J, Kadish AH. DEFINITE Investigators. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1228–1233. doi: 10.1016/j.jacc.2006.05.053.
    1. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, Beshai JF, Langberg JJ. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006;3:881–886. doi: 10.1016/j.hrthm.2006.05.010.
    1. Streitner F, Kuschyk J, Veltmann C, Brueckmann M, Streitner I, Brade J, Neumaier M, Bertsch T, Schumacher B, Borggrefe M, Wolpert C. Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipients--a pilot study. Cytokine. 2007;40(1):30–34. doi: 10.1016/j.cyto.2007.07.187.
    1. Haugen E, Gan LM, Isic A, Skommevik T, Fu M. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol. 2008;13(1):19–24.
    1. Banach M, Goch JH, Ugurlucan M, Mariscalco G, Rysz J. Statins in the prevention of postoperative atrial fibrillation: is there really no effect? Am Heart J. 2008;155(6):e53. doi: 10.1016/j.ahj.2008.03.008.
    1. Guo HM. Anti-arrhythmic effects of statins: a hypothesis remains to be tested. Heart Rhythm. 2008;5(4):511–2. doi: 10.1016/j.hrthm.2008.01.033.
    1. Zimmermann AV, Doehner W, Pérez AV, Schmidt H, Volk HD, Anker SD, Rauchhaus M. The relationship between high-density lipoprotein, bacterial lipopolysaccharide, and tumour necrosis factor-α in patients with acute decompensated heart failure. Arch Med Sci. 2008;4(4):380–385.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する